z-logo
Premium
Systematic review with meta‐analysis: mucosal healing is associated with improved long‐term outcomes in Crohn's disease
Author(s) -
Shah S. C.,
Colombel J.F.,
Sands B. E.,
Narula N.
Publication year - 2016
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.13475
Subject(s) - medicine , meta analysis , odds ratio , crohn's disease , confidence interval , disease , prospective cohort study , gastroenterology , surgery
Summary Background Clinical manifestations of Crohn's disease ( CD ) do not reliably correlate with endoscopic activity. While treating to achieve clinical remission ( CR ) has neither proven to improve CD outcomes nor alter the natural disease course, it is unclear whether targeting objective measures like mucosal healing ( MH ) is associated with improved long‐term outcomes. Aim To perform a systematic review and meta‐analysis comparing long‐term outcomes in active CD patients who achieve MH compared to those who do not. Methods We performed a systematic literature search to identify studies with prospective cohorts of active CD patients that included outcomes of patients who achieved MH at first endoscopic assessment ( MH 1) compared to those who did not. The primary outcome was long‐term (≥50 weeks) CR . Secondary outcomes included CD ‐related surgery‐free rate, hospitalisation‐free rate and long‐term MH rate. Pooled odds ratio ( OR ) and 95% confidence intervals ( CI ) were calculated. Results Twelve studies with 673 patients met inclusion criteria. Patients achieving MH 1 had a pooled OR of 2.80 (95% CI , 1.91–4.10) for achieving long‐term CR , 2.22 (95% CI , 0.86–5.69) for CD ‐related surgery‐free rate, and 14.30 (95% CI , 5.57–36.74) for long‐term MH . Sensitivity analyses suggested no difference in outcomes if MH 1 was achieved on biologics vs. non‐biologics. No significant publication bias or heterogeneity was detected. Conclusions Achieving MH 1 is associated with increased rates of long‐term clinical remission, and maintenance of mucosal healing in active Crohn's disease and may therefore be a reasonable therapeutic target.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom